Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with revenue projections soaring to $4.3B by 2030. Read more here.
ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and ...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every ...
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...